Emergency Department-Initiated Buprenorphine for Opioid Dependence with Continuation in Primary Care: Outcomes During and After Intervention.
Gail D'Onofrio, Marek C Chawarski, Patrick G O'Connor...
https://pubmed.ncbi.nlm.nih.gov/28194688/Actively Recruiting
Led by University of California, Davis · Updated on 2026-06-29
528
Participants Needed
3
Research Sites
13 weeks
Total Duration
This research aims to compare long-term outcomes of buprenorphine treatment for patients with opioid use disorder OUD who start buprenorphine in hospital emergency departments. It evaluates whether referring patients to outpatient buprenorphine treatment via telehealth or in-person clinics leads to better treatment engagement, longer retention, and improved patient experience. The study addresses challenges faced by patients transitioning from emergency care to ongoing OUD treatment, including barriers like transportation and stigma. Participants will be randomized to receive referrals for outpatient OUD treatment either through telehealth phone or video visits or in-person clinics. The study takes place at three emergency departments participating in Californias CA Bridge program, which supports ED-based OUD care including counseling, naloxone provision, and buprenorphine initiation. Those in the telehealth arm receive outpatient treatment remotely, while the in-person arm involves local clinic visits. Both groups receive support from CA Bridge counselors for up to 30 days to help establish outpatient care. During the study, participants answer questionnaires at baseline and at 1, 3, 6, and 9 months after their emergency department visit. Researchers will monitor prescription records to assess buprenorphine retention over six months, track drug-related overdose deaths, hospital visits, and patient experiences using validated surveys. The study also examines how patients feelings of stigma relate to treatment outcomes. Overall, the study seeks to inform better referral practices to improve long-term OUD treatment and reduce overdose risks.
CONDITIONS
Telehealth vs In-Person Evaluation of Addiction Treatment After Visiting the Emergency Department
M
Meghan Weyrich, MPH
S
Stephen Henry, MD MSc
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University of California, Davis
Lead Sponsor
Patient-Centered Outcomes Research Institute
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | Telehealth Referral | In-Person Referral |
|---|---|---|
| What it is | Referral to a telehealth-based outpatient addiction treatment program, provided after receiving buprenorphine for opioid use disorder in the emergency department. | Referral to a traditional in-person outpatient addiction treatment program, following emergency department initiation of buprenorphine for opioid use disorder. |
| Role in the Study | Active intervention arm studying the impact of telehealth referral for OUD treatment. | Active comparator arm representing usual care with in-person referral for OUD treatment. |
| Primary Use | Evaluate whether referral to telehealth outpatient treatment improves retention on buprenorphine after emergency department care. | Assess outcomes with traditional in-person referral to outpatient OUD treatment after emergency department discharge. |
| How it is Delivered | After emergency department initiation of buprenorphine, participants are scheduled for a telehealth follow-up appointment with an outpatient provider. | Participants are linked to an in-person outpatient clinic for follow-up buprenorphine care after leaving the emergency department. |
| Evidence Status | Currently being studied; results for effectiveness in retaining patients on buprenorphine through telehealth referral are not yet established. | Traditional in-person referral for outpatient buprenorphine treatment is established in clinical practice; prior studies link this approach to improved outcomes compared to no referral or usual care. |
| Important Limitations | The telehealth referral pathway is investigational, and its effectiveness may differ across patient groups or require robust telecommunication access. | In-person referral may be limited by transportation challenges, regional access to addiction care, and patient ability to attend clinic visits. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Duration - 9 months
Participants receive buprenorphine in the emergency department and are referred to outpatient treatment via telehealth or in-person clinics. They receive support from counselors to help establish care.
Questionnaires at baseline, 1, 3, 6, and 9 months
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
HEALTH_SERVICES_RESEARCH
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Gail D'Onofrio, Marek C Chawarski, Patrick G O'Connor...
https://pubmed.ncbi.nlm.nih.gov/28194688/University of California, Davis
Lead Sponsor
Patient-Centered Outcomes Research Institute
Collaborating Sponsor